Compound reference
CJC-1295 No DAC
Growth Hormone Research · vial. For laboratory research use only. Not for human or veterinary consumption, diagnostic use, therapeutic use, or clinical use.
Chemistry identity
Reference identifiers
COA documentation
Lot record status
COA on file - lab confirmation pendingView Lab ReportsPublished literature
Research context
Peer-reviewed literature referencing this compound, provided for research context.
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry2026
Uçaktürk E, Nemutlu E
Journal of pharmaceutical and biomedical analysis
Developed and validated a nano-LC-quadrupole/Orbitrap mass spectrometry method for detecting growth hormone-releasing hormone (GHRH) and its synthetic analogs, including CJC-1295, in urine, characterizing their in vivo instability, rapid renal clearance, and low urinary concentrations to meet World Anti-Doping Agency analytical sensitivity requirements.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults2006
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA
The Journal of clinical endocrinology and metabolism
In randomized, placebo-controlled trials in healthy adult volunteers, subcutaneous administration of the long-acting (DAC-conjugated) parent GHRH analog produced sustained, concentration-related increases in plasma growth hormone and insulin-like growth factor-I over multiple days, characterizing the pharmacodynamics of extended GHRH-receptor activation; the estimated elimination half-life for that long-acting form was 5.8-8.1 days.
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog2005
Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al.
Endocrinology
In cultured rat anterior pituitary cells and in rats in vivo, a tetrasubstituted, dipeptidyl-peptidase-IV-resistant analog of human GH-releasing factor (hGRF 1-29) -- the parent peptide underlying CJC-1295 -- retained potent bioactivity, producing a measurable rise in plasma growth hormone after subcutaneous injection and establishing the enzymatic-stability rationale behind the modified GRF(1-29) backbone.
Catalog access requires an account and acceptance of a research-use disclaimer.
This product is intended strictly for research and laboratory use only. It is designated for in vitro testing and experimental purposes. Any use involving human or animal consumption is prohibited by law. All information provided on this website is for educational purposes only. This product must only be handled by licensed, qualified professionals. It is not intended for use as a drug, food, or cosmetic, and must not be misused, mislabeled, or misrepresented as such.